All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Mosunetuzumab in heavily pretreated follicular lymphoma: Phase I dose-escalation trial updates
Featured:
Sarit AssoulineYour opinion matters
Early phase studies of several novel bispecific antibodies are showing promising results for the treatment of R/R B-cell NHL. When considering bispecific antibody therapy, which characteristic/s would primarily drive your treatment choice?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Sarit E. Assouline, Jewish General Hospital, Montreal, CA, about the use of mosunetuzumab in heavily pretreated follicular lymphoma.
Mosunetuzumab in heavily pretreated follicular lymphoma: Phase I dose-escalation trial updates
Assouline provides an update on a phase I trial evaluating mosunetuzumab, a bispecific CD3/CD20 antibody, in patients with relapsed/refractory follicular lymphoma. Assouline outlines the degree of activity, durability, and tolerability of the treatment and discusses future avenues for research.
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?